In real-world clinical practice, Ocrevus (ocrelizumab) showed sustained effectiveness in people with relapsing forms of multiple sclerosis (MS), with most patients remaining free from long-term worsening of disability over four years, according to a new study. Relapse rates and MRI disease activity were also low…
Tweet Now the title of this post seemingly has nothing to do with the content of the paper, but what this new paper says is air poluution is bad for you. We say NSS. However is it the air pollution that is the issue or…
Merck and Mayo Clinic have launched a research collaboration to use artificial intelligence (AI) and large-scale clinical data to accelerate drug discovery and development, with an initial focus on diseases with high unmet needs, including multiple sclerosis (MS). The partnership will combine Mayo’s extensive clinical…
By Dr. Eva Jackson Seeking Answers and Facing Uncertainty For many years, my health declined, and I found myself searching desperately for answers. Ireached out to my healthcare team, at times pleading for their help to uncover what was causingmy … Continue reading → Source:…
Des de la Fundació GAEM volem compartir una bona notícia: hem estat una de les entitats beneficiàries de la Campanya Solidària impulsada per Audax Renovables, rebent una aportació de 1.000 euros per contribuir a la nostra tasca de suport a la recerca biomèdica en esclerosi…
Tweet mmmmM…my favourite subject….Yep my Bad…I don’t know the back end of a flagelleum from the front end…So I will do like every respecting cheat and use AI rather than reading and ask it to tell me what the important bacteria in MS are. Here…
The post People with MS experience pain more frequently than the general population, research reveals appeared first on MS Australia. Source: www.msaustralia.org.au
Tweet Higgins V, Parker ML, Ahmed B, Bhayana V, Booth RA, Chen Y, Collier C, Freedman MS, Gagné M, Ismail OZ, Gifford JL, Macri J, Moore CS, Newbigging A, Olayinka L, Poliakov I, Rodriguez-Capote K, Schneider R, Thebault S, Yang L, Beriault DR. Best practice…
Tweet Alroughani R, Ahmed SF. Treatment outcomes of high-efficacy disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: A longitudinal observational study. Mult Scler Relat Disord. 2026 Jan 19;108:107024. doi: 10.1016/j.msard.2026.107024. Epub ahead of print. Background: The evolution of high-efficacy disease-modifying therapies (HE-DMTs) has significantly shifted the…
Continued treatment with TG Therapeutics’ Briumvi (ublituximab) provides sustained clinical benefits for people with relapsing forms of multiple sclerosis (MS), particularly if started earlier. That’s according to data from the ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) Phase 3 clinical trials and their ongoing open-label…